Prognostic value of aberrant p53 immunoexpression for the recurrence of ependymoma: An analysis of 76 cases

Neuropathology

Volumn 19, Issue 4, 1999, Pages 380-385

  Korshunov, Andrey ^a   Timirgaz, Valery ^a   Golanov, Andrey ^a  

^a BURDENKO NEUROSURGICAL INSTITUTE   (Russian Federation)

Author keywords

Ependymoma; Immunohistochemistry; p53 protein; Prognosis; Recurrence

Indexed keywords

PROTEIN P53;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL FEATURE; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; EPENDYMOMA; FEMALE; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR BIOLOGY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL; SURVIVAL TIME; TUMOR RECURRENCE;

EID: 0033400757     PISSN: 09196544     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1789.1999.00254.x     Document Type: Article

References (41)

1. Applegate GL, Marymont M. Intracranial ependymomas: A Review. Cancer Invest 1998; 16: 588-593.
2. Bouffet E, Perilongo G, Canete A et al. Intracranial ependymomas in children: a critical review of prognostic factors and a plea for cooperation. Med Pediatr Oncol 1998; 30: 319-329.
3. Ernestus RI, Schröder R, Stützer H et al. The clinical and prognostic relevance of grading in intracranial ependymomas. Br J Neurosurg 1997; 11: 421-428.
4. Foreman NK, Love S, Thorne R. Intracranial ependymomas: analysis of prognostic factors in a population-based series. Pediatr Neurosurg 1996; 24: 119-125.
5. Gerszten PC, Pollack IF, Martínez AJ et al. Intracranial ependymomas of childhood. Lack of correlation of histopathology and clinical outcome. Pathol Res Pract 1996; 192: 515-522.
6. Kovalic JJ, Flaris N, Grigsby PW et al. Intracranial ependymoma long-term outcome, patterns of failure. J Neurooncol 1993; 15: 125-131.
7. McLaughlin MP, Marcus RBJ, Buatti JM et al. Ependymoma: results, prognostic factors and treatment recommendations. Int J Radiat Oncol Biol Phys 1998; 40: 845-850.
8. Nazar GB, Hoffman HJ, Becker LE et al. Infratentorial ependymomas in childhood: prognostic factors and treatment. J Neurosurg 1990; 72: 408-417.
9. Perilongo G, Massimino M, Sotti G et al. Analyses of prognostic factors in a retrospective review of 92 children with ependymoma: Italian Pediatric Neurooncology Group. Med Pediatr Oncol 1997; 29: 79-85.
10. Pollack IF, Gerszten PC, Martinez AJ et al. Intracranial ependymomas of childhood: long-term outcome and prognostic factors. Neurosurgery 1995; 37: 655-666.
11. Robertson PL, Zeltzer PM, Boyett JM et al. Survival and prognostic factors following radiation therapy and chemotherapy for ependymomas in children: a report of the Children's Cancer Group. J Neurosurg 1998; 88: 695-703.
12. Ross GW, Rubinstein LJ. Lack of histopathological correlation of malignant ependymomas with post-operative survival. J Neurosurg 1989; 70: 31-36.
13. Schiffer D, Chio A, Cravioto H et al. Ependymoma: internal correlations among pathological signs: the anaplastic variant. Neurosurgery 1991; 29: 206-210.
14. Sutton LN, Goldwein J, Perilongo G et al. Prognostic factors in childhood ependymomas. Pediatr Neurosurg 1997; 16: 57-65.
15. Asai A, Hoshino T, Edwards MS et al. Predicting the recurrence of ependymomas from the bromodeoxyuridine labelling index. Childs Nerv Syst 1992; 8: 273-278.
16. Figarella-Branger D, Gambarelli D, Dollo C et al. Infratentorial ependymomas of childhood. Correlation between histological features, immunohistological phenotype, silver nucleolar organiser region staining values and postoperative survival in 16 cases. Acta Neuropathol (Berl) 1991; 82: 208-216.
17. Schiffer D, Chio A, Giordana MT et al. Proliferating cell nuclear antigen expression in brain tumours, and its prognostic role in ependymomas: an immunohistochemical study. Acta Neuropathol (Berl) 1993; 85: 495-502.
18. Schroder R, Ploner C, Ernestus RG. The growth potential of ependymomas with varying grades of malignancy measures with the KI-67 labelling index and mitotic index. Neurosurg Rev 1993; 16: 145-150.
19. Levine AJ. Tumor suppressor genes. In: Levine AJ, Schmidek HH (eds). Molecular Genetics Of Nervous System Tumors. New York: Wiley-Liss, 1993; 137-43.
20. Lane DP. On the expression of the p53 protein in human cancer. Mol Biol Rep 1994; 19: 23-29.
21. Baxendine-Jones J, Campbell I, Ellison D. P53 status has no prognostic significance in glioblastomas treated with radiotherapy. Clin Neuropathol 1997; 16: 332-336.
22. Chozick BS, Pezullo JC, Epstein MH, Finch PW. Prognostic implications of p53 overexpression in supratentorial astrocytic tumours. Neurosurgery 1994; 35: 831-838.
23. Cunningham JM, Kimmel DW, Scheithauer BW, O'Fallon JR, Novotny PJ, Jenkins RB. Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: relationships and prognostic value. J Neurosurg 1997; 86: 121-130.
24. Danks RA, Chopra G, Gonzales MF, Orian JM, Kaye AH. Aberrant p53 expression does not correlate with the prognosis of anaplastic astrocytoma. Neurosurgery 1994; 37: 246-254.
25. Hilton DA, Love S, Barber R, Ellison D, Sanderman D. Accumulation of p53 and Ki-67 expression do not predict survival in patients with fibrillary astrocytoma or the response of these tumours to radiotherapy. Neurosurgery 1998; 42: 724-729.
26. Korkolopoulou P, Christodoulou P, Kouzelis K et al. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferating markers and epidermal growth factors receptor. Br J Cancer 1997; 75: 1269-1278.
27. Kyritsis AP, Xu R, Bondy ML, Levin VA, Bruner JM. Correlation of p53 immunoreactivity and sequencing in patients with glioma. Mol Carcinog 1996; 15: 14-18.
28. Rainov NG, Dobberstein KU, Bahn H et al. Prognostic factors in malignant glioma: influence of the overexpression of oncogene and tumor-suppressor gene products on survival. J Neurooncol 1997; 35: 13-28.
29. Soini Y, Nyemela A, Kamel D et al. p53 immunohistochemical positivity as a prognostic marker in intracranial tumours. APMIS 1993; 102: 786-792.
30. Schiffer D, Dutto A, Cavalla P et al. Prognostic factors in oligodendroglioma. Can J Neurol Sci 1997; 24: 313-319.
31. Jaros E, Lunec J, Perry RH et al. p53 protein overexpression identifies a group of central primitive neuroectodermal tumours with poor prognosis. Br J Cancer 1993; 68: 801-807.
32. Karamitopoulou E, Perentes E, Diamantis I. p53 protein expression in central nervous system tumours: an immunohistochemical study with CM1 polyvalent and DO-7 monoclonal antibodies. Acta Neuropathol (Berl) 1993; 85: 611-616.
33. Rushing EJ, Brown DF, Hladic CL, Risser RC, Mickey BE, White CL. Correlation of bcl-2, p53 and MIB-1 expression with ependymoma grade and subtypes. Mod Pathol 1998; 11: 464-467.
34. LeBlanc M, Crowley J. Relative risk trees for censored survival. Biometrics 1992; 48: 411-425.
35. Bhattacharjee MB, Armstrong DD, Vogel H et al. Cytogenetic analysis of 120 primary pediatric brain tumors and literature review. Cancer Genet Cytogenet 1997; 97: 39-53.
36. Bijlsma EK, Voesten AM, Bijleveld EH et al. Molecular analysis of genetic changes in ependymomas. Genes Chromosomes Cancer 1995; 13: 272-277.
37. Haken von HM, White EC, Daneshvar SL et al. Molecular genetic analysis of chromosome arm 17p and chromosome arm 22q DNA sequences in sporadic pediatric ependymomas. Genes Chromosomes Cancer 1996; 17: 37-44.
38. Fink KL, Rushing EJ, Schold SC, Nisen PD. Infrequency of p53 gene mutation in ependymomas. J Neurooncol 1996; 27: 111-115.
39. Kramer DL, Parmiter AH, Rorke LB et al. Molecular cytogenetic studies of pediatric ependymomas. J Neurooncol 1998; 37: 25-33.
40. Ohgaki H, Eibl RH, Wiestler OD, Yasargil MG, Newcomb EW, Kleihues P. p53 mutations in non-astrocytic human brain tumors. Cancer Res 1991; 51: 6202-6205.
41. Tominaga T, Kayama T, Kumabe T, Sonoda Y, Yoshimoto T. Anaplastic ependymomas: clinical features and tumour suppressor gene p53 analysis. Acta Neurochir (Wien) 1995; 135: 163-170.